Condition: Sjögren · Sjogren Disease · Sjogren's Syndrome · Sponsor: Cullinan Therapeutics Inc.
A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.
This description comes directly from the study's public registry record.
Amy Gubits, MPH · +1 617 410 4650 · ClinOps@cullinantx.com
Always discuss trial participation with your own doctor first.
| Cullinan Investigative Site | Orlando, Florida, United States | Recruiting |
| Cullinan Investigative Site | Memphis, Tennessee, United States | Recruiting |
| Cullinan Investigative Site | Plano, Texas, United States | Recruiting |
| Cullinan Investigative Site | Webster, Texas, United States | Recruiting |
| Cullinan Investigative Site | Salt Lake City, Utah, United States | Recruiting |
| Cullinan Investigative Site | Brest, France | Recruiting |
| Cullinan Investigative Site | Le Kremlin-Bicêtre, France | Recruiting |
| Cullinan Investigative Site | Strasbourg, France | Recruiting |
| Cullinan Investigative Site | Erlangen, Germany | Recruiting |
| Cullinan Investigative Site | Hanover, Germany | Recruiting |
| Cullinan Investigative Site | Roma, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07041099